Core Viewpoint - Chuangsheng Group-B (06628) has seen a significant stock price increase of over 10%, currently trading at 4.82 HKD, following the announcement of a strategic cooperation agreement with Huajian Medical (01931) regarding the potential tokenization of innovative drug pipeline assets [1] Group 1: Strategic Cooperation - Chuangsheng Group has entered into a strategic cooperation agreement with Huajian Medical to explore the tokenization of its innovative drug pipeline assets [1] - The agreement involves integrating six core innovative drug pipeline assets (TST003, TST005, TST786, TST105, TST106, and TST013) into its U.S. entity [1] - The collaboration aims to utilize Huajian Medical's ETHK global innovative drug intellectual property RWA exchange for potential RWA tokenization [1] Group 2: Funding and Development - If the token issuance is successful, the proceeds will be used to accelerate the clinical and preclinical development of several innovative antibody projects targeting tumors [1] - The Chairman of Chuangsheng Group, Dr. Qian Xueming, emphasized the need for substantial funding in the long and high-risk process of drug development [1] - The partnership with Huajian Medical's on-chain RWA digital platform will provide a new funding channel by allowing the intellectual property of innovative drug pipelines to be packaged into a U.S. SPV for novel financing [1]
港股异动 | 创胜集团-B(06628)尾盘涨逾10% 携手华检医疗将15亿美元创新药管线资产RWA代币化